Avicennai.AI first fundraising
Avicenna.AI secured its initial capital infusion of $2.7 million through investments from the French companies Innovacom and CEMAG Invest.
CINA, a suite of AI tools for Stroke
Avicenna.AI introduced its first products, CINA-ICH and CINA-LVO, triage tools for stroke detection. Both solutions obtained the CE-marking in March, swiftly followed by FDA clearance in June.
CINA Chest for thoraco-abdominal pathologies
FDA clearance and Launch of CINA-ASPECTS
In May 2021, Avicenna.AI successfully obtained FDA clearance for CINA-PE and CINA-AD, while also launching and securing the CE marking for its new Stroke quantification tool, CINA-ASPECTS.
Avicenna.AI Serie A fundraising
Avicenna.AI secured a Series A funding round, bringing aggregated investment close to $10 million. The round was backed by existing investors Innovacom and CEMAG Invest.
Introduction of the Incidental Suite
Avicenna.AI introduced its new Incidental findings Suite, with the launch of CINA-iPE for unsuspected Pulmonary Embolism detection.
FDA-Clearance for CINA-ASPECTS and CINA-iPE
Avicenna.AI Secures Two FDA Clearances For Stroke Assessment And Opportunistic Pulmonary Embolism.